Carlson College of Veterinary Medicine

L. E. Bermudez and Kaplan, G., “Recombinant cytokines for controlling mycobacterial infections.”, Trends in microbiology, vol. 3, no. 1, pp. 22-7, 1995.

L. E. Bermudez and Young, L. S., “Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex.”, Journal of leukocyte biology, vol. 48, no. 1, pp. 67-73, 1990.

L. E. Bermudez, Martinelli, J., Petrofsky, M., Kolonoski, P., and Young, L. S., “Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model.”, The Journal of infectious diseases, vol. 169, no. 3, pp. 575-80, 1994.

L. E. Bermudez and Petrofsky, M., “Regulation of the expression of Mycobacterium avium complex proteins differs according to the environment within host cells.”, Immunology and cell biology, vol. 75, no. 1, pp. 35-40, 1997.

N. Hsu, Young, L. S., and Bermudez, L. E., “Response to stimulation with recombinant cytokines and synthesis of cytokines by murine intestinal macrophages infected with the Mycobacterium avium complex.”, Infection and immunity, vol. 63, no. 2, pp. 528-33, 1995.

L. E. Bermudez, Young, L. S., and Inderlied, C. B., “Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.”, Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.

L. E. Bermudez, Goodman, J., and Petrofsky, M., “Role of complement receptors in uptake of Mycobacterium avium by macrophages in vivo: evidence from studies using CD18-deficient mice.”, Infection and immunity, vol. 67, no. 9, pp. 4912-6, 1999.

J. H. Champsi, Bermudez, L. E., and Young, L. S., “The role of cytokines in mycobacterial infection.”, Biotherapy (Dordrecht, Netherlands), vol. 7, no. 3-4, pp. 187-93, 1994.

L. Danelishvili and Bermudez, L. E., “Role of type I cytokines in host defense against Mycobacterium avium infection.”, Current pharmaceutical design, vol. 9, no. 1, pp. 61-5, 2003.

S. R. Byrd, Gelber, R., and Bermudez, L. E., “Roles of soluble fibronectin and beta 1 integrin receptors in the binding of Mycobacterium leprae to nasal epithelial cells.”, Clinical immunology and immunopathology, vol. 69, no. 3, pp. 266-71, 1993.

L. E. Bermudez, Kolonoski, P., and Young, L. S., “Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.”, Antimicrobial agents and chemotherapy, vol. 40, no. 4, pp. 1033-5, 1996.

L. Danelishvili, Yamazaki, Y., Selker, J., and Bermudez, L. E., “Secreted Mycobacterium tuberculosis Rv3654c and Rv3655c proteins participate in the suppression of macrophage apoptosis.”, PloS one, vol. 5, no. 5, p. e10474, 2010.

A. E. Parker and Bermudez, L. E., “Sequence and characterization of the glyceraldehyde-3-phosphate dehydrogenase of Mycobacterium avium: correlation with an epidermal growth factor binding protein.”, Microbial pathogenesis, vol. 28, no. 3, pp. 135-44, 2000.

M. J. Harriff, Wu, M., Kent, M. L., and Bermudez, L. E., “Species of environmental mycobacteria differ in their abilities to grow in human, mouse, and carp macrophages and with regard to the presence of mycobacterial virulence genes, as observed by DNA microarray hybridization.”, Applied and environmental microbiology, vol. 74, no. 1, pp. 275-85, 2008.

L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S., “SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.”, Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.

L. E. Bermudez, Inderlied, C., and Young, L. S., “Stimulation with cytokines enhances penetration of azithromycin into human macrophages.”, Antimicrobial agents and chemotherapy, vol. 35, no. 12, pp. 2625-9, 1991.

G. Carter, Young, L. S., and Bermudez, L. E., “A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.”, Antimicrobial agents and chemotherapy, vol. 48, no. 12, pp. 4907-10, 2004.

M. McNamara, Tzeng, S. - C., Maier, C., Zhang, L., and Bermudez, L. E., “Surface proteome of "Mycobacterium avium subsp. hominissuis" during the early stages of macrophage infection.”, Infection and immunity, vol. 80, no. 5, pp. 1868-80, 2012.

M. McNamara, Tzeng, S. - C., Maier, C., Wu, M., and Bermudez, L. E., “Surface-exposed proteins of pathogenic mycobacteria and the role of cu-zn superoxide dismutase in macrophages and neutrophil survival.”, Proteome science, vol. 11, no. 1, p. 45, 2013.

L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P., and Young, L. S., “Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.”, Antimicrobial agents and chemotherapy, vol. 45, no. 8, pp. 2210-4, 2001.

L. E. Bermudez, Reynolds, R., Kolonoski, P., Aralar, P., Inderlied, C. B., and Young, L. S., “Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.”, Antimicrobial agents and chemotherapy, vol. 47, no. 8, pp. 2685-7, 2003.

R. B. Cope, Stang, B. V., Valentine, B. A., and Bermudez, L. E., “Topical exposure to exogenous ultraviolet-irradiated urocanic acid enhances Mycobacterium ulcerans infection in a Crl:IAF(HA)-hrBR hairless guinea-pig model of Buruli ulcer disease.”, Photodermatology, photoimmunology & photomedicine, vol. 20, no. 1, pp. 14-20, 2004.

L. E. Bermudez, Yau-Young, A. O., Lin, J. P., Cogger, J., and Young, L. S., “Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides.”, The Journal of infectious diseases, vol. 161, no. 6, pp. 1262-8, 1990.

L. E. Bermudez, Stevens, P., Kolonoski, P., Wu, M., and Young, L. S., “Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor.”, Journal of immunology (Baltimore, Md. : 1950), vol. 143, no. 9, pp. 2996-3000, 1989.

L. E. Bermudez, Petrofsky, M., and Stevens, P., “Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.”, Immunology, vol. 94, no. 3, pp. 297-303, 1998.